Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy

Summary

This study is an investigator-initiated, phase II, single arm, open label clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at moderate or high risk for poor outcome, defined as an NCCN-IPI score of 2 or higher. All subjects will receive investigational drug, and outcomes will be compared to historical controls.

Timeline

Start

2024-01

Primary completion

2027-01

Completion

2028-01

Drugs

Indications